Overview: Mircera is used to treat anemia. Common side effects include diarrhea and pain or swelling in the nose or throat. Serious side effects are rare but include blood clots, seizures, and severe ...

Results from two recent studies show for the first time that chronic kidney disease patients on dialysis as well as those not on dialysis, who need correction of renal anemia, were effectively treated ...

Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin levels in chronic kidney disease ...

IN 2015 VIFOR PHARMA (FORMERLY A COMPANY OF GALENICA GROUP) ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ROCHE FOR THE COMMERCIALISATION OF ITS MEDICINE MIRCERA ® in the US. MIRCERA ® IS A ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Mircera" drug pipelines has been added to ResearchAndMarkets.com's offering. Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a ...

MIRCERA (methoxy polyethylene glycol-epoetin beta), a PEGylated EPO, is a synthetic protein that helps the body produce red blood cells and used to treat anemia caused by kidney disease. The drug is ...

The battle between Roche and Amgen over the former’s bid to launch Mircera has taken a fresh turn with the news that the Swiss firm is appealing against a preliminary court injunction that prevents US ...

The US Food and Drug Administration has approved Mircera (methoxy polyethylene glycol-epoetin beta) (for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are converting ...

maintained Hb levels as effectively as more frequently-dosed ESAs, in patients with the lowest baseline Hb who are difficult to treat. - In the correction studies, the mean baseline low Hb in the ...